Ignite Creation Date:
2024-05-05 @ 10:29 PM
Last Modification Date:
2024-10-26 @ 10:19 AM
Study NCT ID:
NCT01122329
Status:
COMPLETED
Last Update Posted:
2015-03-23
First Post:
2010-05-11
Brief Title:
A Positron Emission Tomography PET Study Evaluating Brain Metabolism of a Medical Food in Alzheimers Disease
Sponsor:
University of California Los Angeles
Organization:
University of California Los Angeles
Study Overview
Official Title:
A Single-site Positron Emission Tomography PET Study of the Cerebral Metabolic Effects of AC-1202 Axona Treatment in Mild-to-Moderate Alzheimers Disease AD
Status:
COMPLETED
Status Verified Date:
2015-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AD
Brief Summary:
This study will examine the brain metabolic effects of AC-1202 Axona a medical food for Alzheimers disease Subjects who meet entry criteria will undergo H215O positron emission tomography prior to and 90 minutes after consumption of Axona at baseline and then again after 45 days of treatment Cognitive testing will also be conducted at baseline and day 45
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None